In July 1997, AMRI received a $100,000 grant from the National Cancer Institute to "design and synthesize compounds that inhibit a class of enzymes responsible for regulation of the cell cycle" [REF].
In October 2012, AMRI announced a five-year extension of an API supply agreement with Shire for an undisclosed product [REF].